Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have been a significant part of the pharmaceutical industry in Tunisia. The market has witnessed a surge in demand for antiviral drugs over the last few years.
Customer preferences: The rising prevalence of viral diseases and infections has resulted in an increase in the demand for antiviral drugs. The customers in Tunisia are becoming more aware of the benefits of antiviral drugs and are willing to spend on them. The customers prefer the drugs that are effective against a wide range of viruses, have fewer side effects, and are affordable.
Trends in the market: The antiviral drugs market in Tunisia is witnessing a trend of increased investment in research and development. The companies are focusing on developing new drugs that are more effective against different viruses. The market is also witnessing an increase in the number of mergers and acquisitions, which is leading to the consolidation of the market. The companies are also focusing on expanding their product portfolio to cater to the growing demand for antiviral drugs.
Local special circumstances: Tunisia has a high prevalence of viral diseases such as HIV, hepatitis, and influenza. The government has taken several initiatives to control the spread of these diseases, which has led to an increase in the demand for antiviral drugs. The government has also introduced several policies to encourage the development and manufacturing of antiviral drugs in the country.
Underlying macroeconomic factors: The pharmaceutical industry in Tunisia is witnessing a steady growth due to the increasing demand for drugs and the government's support. The country has a stable economy, which has resulted in an increase in the purchasing power of the customers. The government's initiatives to promote the pharmaceutical industry have also attracted foreign investment, which has led to the growth of the industry. The increasing number of hospitals and healthcare facilities in the country has also contributed to the growth of the antiviral drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
